Blog
December 11, 2025
According to MDLinx, Rofecoxib (Vioxx) — Merck’s blockbuster COX-2 selective anti-inflammatory drug — was withdrawn in 2004 after long-term clinical data revealed a significant increase in heart attack and stroke risk.
This single mechanistic toxicology failure erased more than $30 billion in market value, triggered historic litigation, and permanently reshaped FDA’s cardiovascular risk requirements.
December 10, 2025
How Troglitazone’s Hepatotoxicity Changed Drug Development Forever — and Why It Still Matters Today Troglitazone (Rezulin), introduced by Warner-Lambert and later absorbed by Pfizer, was once celebrated as a breakthrough insulin-sensitizing therapy for type 2 diabetes. Within a few years, it became one of the most catastrophic toxicology failures in FDA history — linked to idiosyncratic yet sometimes fatal liver injury, multiple cases of acute liver failure, and a full U.S. market withdrawal in 2000.
December 9, 2025
According to The Hill, a widely used high-blood-pressure medication was voluntarily recalled after FDA testing identified contamination and quality issues that could pose serious risks to patients. https://thehill.com/policy/healthcare/5636604-high-blood-pressure-medication-voluntarily-recalled-fda Why do these recalls keep happening? Because wherever chemistry, manufacturing, and patient exposure intersect — toxicology decides the outcome. Here’s the one idea you should take away:
December 8, 2025
Pharmaceuticals enter the environment via patient excretion, improper disposal, and manufacturing waste, prompting regulators worldwide to require environmental risk assessments (ERAs) as part of drug approvals. In an ERA, predicted environmental concentrations (PECs) of a drug are compared to ecotoxicity thresholds, often in a tiered fashion (Phase I screening followed by Phase II testing) [1]. This report analyzes ERA regulations and practice globally, from the EU and US to emerging regions in Asia, Latin America, the Middle East, and Africa. It integrates recent developments in China, India, Brazil, the Gulf Cooperation Council (GCC) countries, ASEAN nations, and African markets, alongside established frameworks (EU, US, Canada, Japan, Australia). Key findings include:
